Selected publications

Clinical registries run by us have led to dozens of articles in peer-reviewed journals. The following list provides the most important of them.

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

2018

• Májek O, Anttila A, Arbyn M, van Veen EB, Engesæter B, Lönnberg S. The legal framework for European cervical cancer screening programmes. European Journal of Public Health 2018. [Epub ahead of print] [Cervix]

2017

• Büchler T, Poprach A, Bortlíček Z, et al. Outcomes of patients with long-term treatment response to vascular endothelial growth factor-targeted therapy for metastatic renal cell cancer. Clinical Genitourinary Cancer 2017; 15(6): e1047-e1053. [RENIS]
• Chatzidionysiou K, Lie E, Lukina G, et al. Rituximab retreatment in rheumatoid arthritis in a real-life cohort: data from the CERERRA collaboration. Journal of Rheumatology 2017; 44(2): 162–169. [ATTRA]
• Doubková M, Švancara J, Svoboda M et al. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. The Clinical Respiratory Journal 2017 [Epub ahead of print]. [EMPIRE]
• Fiala O, Hošek P, Pešek M, et al. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Neoplasma 2017; 64(4): 605-610. [TULUNG]
• Fiala O, Pešek M, Skřičková J, et al. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. Tumor Biology 2017; 39(2): 1010428317691186. [TULUNG]
• Iannone F, Courvoisier DS, Gottenberg JE, et al. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). Clinical Rheumatology 2017; 36(4): 773–779. [ATTRA]
• Kala P, Blaha M, Mates M, et al. Czech TAVI registry – hospital outcome. Cor et Vasa 2017; 59(1): e51-e56. [TAVI]
• Koblížek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. European Respiratory Journal 2017; 49(5): 1601446. [POPE]
• Kopečková K, Büchler T, Bortlíček Z, et al. Regorafenib in the real-life clinical practice: Data from the Czech registry. Targeted Oncology 2017; 12(1): 89-95. [CORECT]
• Lakomý R, Poprach A, Bortlíček Z, et al. Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC Cancer 2017; 17: 880. [RENIS]
• Májek O, Dušková J, Dvořák V, et al. Performance indicators in a newly established organized cervical screening programme: registry-based analysis in the Czech Republic. European Journal of Cancer Prevention 2017; 26(3): 232-239. [Cervix]
• Motovska Z, Hlinomaz O, Kala P, et al. One-year outcomes of prasugrel versus ticagrelor in acute myocardial infarction treated with primary angioplasty: the PRAGUE-18 study. Journal of the American College of Cardiology 2017 [Epub ahead of print]. [Prague 18]
• Sandecká V, Hájek R, Pour L, et al. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. European Journal of Haematology 2017; 99(1): 80-90. [RMG]
• Špinar J, Jarkovský J, Špinarová L, et al. Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial. ESC Heart Failure 2017; 4(1): 8-15. [AHEAD]
• Tudoric N, Koblížek V, Miravitlles M, et al. GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort. European Respiratory Journal 2017; 49(4): 1602518. [POPE]

2016

• Buchler T, Bortlicek Z, Poprach A, et al. Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis. European Urology 2016; 70(3): 469–475. [Renis]
• Fiala O, Buchler T, Mohelnikova-Duchonova B, et al. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumor Biology 2016; 37: 6823–6830. [Corect]
• Fiala O, Pesek M, Finek J, et al. Epidermal growth factor receptor gene amplification in patients with advanced-stage NSCLC. Anticancer Research 2016; 36(1): 455–460. [Tulung]
• Fiala O, Pesek M, Finek J, et al. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. Neoplasma 2016; 63(3): 471–476. [Tulung]
• Fiala O, Pesek M, Finek J, et al. Pemetrexed versus erlotinib in the second-line treatment of patients with advanced-stage non-squamous NSCLC harboring wild-type EGFR gene. Anticancer Research 2016; 36(1): 447-453. [Tulung]
• Fiala O, Pešek M, Fínek J, et al. Prognostic significance of serum tumor markers in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Anticancer Research 2016; 36(1): 461-466. [Tulung]
• Fiala O, Pesek M, Finek J, et al. Change in serum lactate dehydrogenase is associated with outcome of patients with advanced-stage NSCLC treated with erlotinib. Anticancer Research 2016; 36(5): 2459-2465. [Tulung]
• Gottenberg JE, Courvoisier DS, Hernandez MV et al. Brief Report: Association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-European registry analysis. Arthritis & Rheumatology 2016; 68(6): 1346–1352. [ATTRA]
• Kiss I, Mlcochova J, Bortlicek Z, et al. Efficacy and toxicity of panitumumab after progression on cetuximab and predictive value of MiR-31-5p in metastatic wild-type KRAS colorectal cancer patients. Anticancer Research 2016; 36(9): 4955-4959. [Corect]
• Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention multicenter randomized PRAGUE-18 study. Circulation 2016; 134(21): 1603-1612. [Prague 18]
• Poprach A, Lakomý R, Bortlíček Z, et al. Efficacy of sunitinib in elderly patients with metastatic renal cell carcinoma: data from real-world clinical practice. Drugs & Aging, 2016; 33(9): 655-663. [Renis]
• Soukup T, Nekvindova J, Dosedel M, et al. Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins. International Journal of Immunopathology and Pharmacology 2016; 29(4): 790–795. [ATTRA]
• Spinar J, Jarkovsky J, Spinarova L, et al. AHEAD score – Long-term risk classification in acute heart failure. International Journal of Cardiology 2016; 202: 21-26. [AHEAD]
• Svaton M, Fiala O, Pesek M, et al. The prognostic role of KRAS mutation in patients with advanced NSCLC treated with second- or third-line chemotherapy. Anticancer Research 2016; 36(3): 1077-1082. [Tulung]
• Uvizl R, Adamus M, Cerny V, et al. Patient survival, predictive factors and disease course of severe sepsis in Czech intensive care units: a multicentre, retrospective, observational study. Biomedical Papers 2016; 160(2): 287-297. [EPOSS]
• Vry J, Gramsch K, Rodger S, et al. European cross-sectional survey of current care practices for Duchenne muscular dystrophy reveals regional and age-dependent differences. Journal of Neuromuscular Diseases 2016; 3(4): 517–527. [REaDY]
• Walker UA, Jaeger VK, Chatzidionysiou K, et al. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. Rheumatology (Oxford) 2016; 55(2): 230–236. [ATTRA]
• Závada J, Uher M, Sisol K, et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Annals of the Rheumatic Diseases 2016; 75: 96–102. [ATTRA]
• Zbozinkova Z, Barczyk A, Tkacova R, et al. POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe. International Journal of Chronic Obstructive Pulmonary Disease 2016; 11(1): 611–622. [POPE]

2015

• Bencsikova B, Bortlicek Z, Halamkova J, et al. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterology 2015; 15: 37. [Corect]
• Chrapek O, Jarkovský J, Studnička J, et al. The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry. Biomedical Papers 2015; 159(3): 407–412. [Amadeus]
• Chrapek O, Jarkovský J, Šín M, et al. Prognostic factors of early morphological response to treatment with ranibizumab in patients with wet age-related macular degeneration. Journal of Ophthalmology 2015; article ID 867479. [Amadeus]
• Fiala O, Pešek M, Fínek J, et al. High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. Tumor Biology 2015; 36(12): 9215–9222. [Tulung]
• Fiala O, Pešek M, Fínek J, et al. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. Tumor Biology 2015; 36(8): 5801–5805. [Tulung]
• Finckh A, Neto D, Iannone F, et al. The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open 2015; 1(1):e000040. [ATTRA]
• Joensuu H, Rutkowski P, Nishida T, et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. Journal of Clinical Oncology 2015; 33(6): 634–642. [reGISTer]
• Kearsley-Fleet L, Závada J, Hetland ML et al. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford) 2015; 54(6): 1074–1079. [ATTRA]
• Kocakova I, Kocak I, Spelda S, et al. Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours. Bratislava Medical Journal 2015; 116(4): 218–221. [reGISTer]
• Kubáčková K, Bortlíček Z, Pavlík T, et al. Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry. Targeted Oncology 2015; 10(3): 385–392. [Renis]
• Kubáčková K, Bortlíček Z, Pikus T, et al. Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data. Future Oncology 2015; 11(2): 225–232. [Corect]
• Littnerova S, Parenica J, Spinar J, et al. Positive influence of being overweight/obese on long term survival in patients hospitalised due to acute heart failure. PLoS One 2015; 10(2): e0117142. [AHEAD]
• Minarik J, Pavlicek P, Pour, et al. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One 2015; 10(4): e0123866. [RMG]
• Poprach A, Bortlíček Z, Melichar B, et al. Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. European Journal of Cancer 2015; 51(4): 507–513. [Renis]
• Ramlau R, Cufer T, Berzinec P, et al. Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study. Journal of Thoracic Oncology 2015; 10(9):1370-1374. [INSIGHT]
• Stourac P, Blaha J, Klozova R, et al. Anesthesia for cesarean delivery in the Czech Republic: a 2011 national survey. Anesthesia & Analgesia 2015; 120(6): 1303-1308. [OBAAMA-CZ]
• Voháňka S, Parmová O, Mazanec R, Strenková J, Ridzoň P, Ehler E, Vávra A, Forgáč M, Junkerová J, Božovský T, Kunc P. Myotonic dystrophy in Czech Republic: data from the national registry. Journal of the Neurological Sciences 2015; 357(Suppl 1): e347–e348. [REaDY]
• Vyskočilová K, Špinarová L, Špinar J, et al. Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure. Biomedical Papers 2015; 159(3):429–436. [AHEAD]

2014

• Bladen CL, Thompson R, Jackson JM, et al. Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. Journal of Neurology 2014; 261(1): 152–163. [REaDY]
• Blatný J, Mathew P, Monagle P, Ovesna P, Fiamoli V. Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry. Blood Coagulation & Fibrinolysis 2014; 25(4):326-332. [SeveN BleeP]
• Büchler T, Bortlíček Z, Poprach A, et al. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. Urologic Oncology: Seminars and Original Investigations 2014; 32(5): 569-575. [Renis]
• Büchler T, Pavlík T, Melichar B, et al. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer 2014; 14: 323. [Corect]
• Jansa P, Jarkovský J, Al-Hiti H, et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulmonary Medicine 2014; 14:45. [REPLY]
• Kiss I, Bortlíček Z, Melichar B, et al. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma. Anticancer Research 2014; 34(2): 949-954. [Corect]
• Kubiczková L, Kryukov F, Slabý O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014; 99(3): 511–518. [RMG]
• Lynge E, Ponti A, James T, et al. Variation in detection of ductal carcinoma in situ during screening mammography: A survey within the International Cancer Screening Network. European Journal of Cancer 2014; 50(1): 185–192. [mamo.cz]
• Novotna B, Koblizek V, Zatloukal J, et al. Czech multicenter research database of severe COPD. International Journal of Chronic Obstructive Pulmonary Disease 2014; 9: 1265–1274. [CHOPN]
• Parmova O, Vohanka S, Strenkova J. The character and frequency of muscular pain in myotonic dystrophy and their relationship to myotonia. International Journal of Neurology and Neurotherapy 2014; 1: 9. [REaDY]
• Poprach A, Pavlík T, Melichar B, et al. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urologic Oncology: Seminars and Original Investigations 2014; 32(4): 488-495 [Renis]
• Ponti A, Lynge E, James T, et al. International variation in management of screen-detected ductal carcinoma in situ of the breast. European Journal of Cancer 2014; 50(15): 2695–2704. [mamo.cz]
• Salaj P, Kubes R, Cetkovsky P, et al. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry. Thrombosis Research 2014; 133(2): 162-167. [HemoRec]
• Slavíček L, Pavlík T, Tomášek J, et al. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterology 2014, 14: 53. [Corect]
• Strenková J, Voháňka S, Haberlová J, et al. REaDY: český registr svalových dystrofií. Česká a slovenská neurologie a neurochirurgie 2014; 77(2): 230-234. [REaDY]
• Suchánek S, Májek O, Vojtěchová G, et al. Colorectal cancer prevention in the Czech Republic: time trends in performance indicators and current situation after 10 years of screening. European Journal of Cancer Prevention 2014; 23(1): 18–26. [kolorektum.cz]
• Toušek P, Toušek F, Horák D, et al. The incidence and outcomes of acute coronary syndromes in a central European country: results of the CZECH-2 registry. International Journal of Cardiology 2014; 173(2): 204-208. [Czech-2]
• Václavík J, Špinar J, Vindiš D, et al. ECG in patients with acute heart failure can predict in-hospital and long-term mortality. Internal and Emergency Medicine 2014, 9(3): 283-291. [AHEAD]
• Zavoral M, Suchánek S, Májek O, et al. Colorectal cancer screening: 20 years of development and recent progress. World Journal of Gastroenterology 2014; 20(14): 3825–3834. [kolorektum.cz]

2013

• Bladen CL, Rafferty K, Straub V, et al. The TREAT-NMD duchenne muscular dystrophy registries: Conception, design, and utilization by industry and academia. Human Mutation 2013; 34(11): 1449-1457. [REaDY]
• Fiala O, Pešek M, Fínek J,et al. Erlotinib in the treatment of advanced squamous cell NSCLC. Neoplasma 2013, 60 (6): 676-682. [Tulung]
• Fiala O, Pešek M, Fínek J, et al. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma 2013, 60 (1): 26-32. [Tulung]
• Horák P, Skácelová M, Hejduk K, et al. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic – data from the ATTRA registry. Clinical Rheumatology 2013; 32:1451-1458. [ATTRA]
• Hronek M, Kovařík M, Aimová P, et al. Skinfold anthropometry – the accurate method for fat free mass measurement in COPD. COPD 2013; 10(5): 597-603. [CHOPN]
• Kalita Z. Národní registr cévních mozkových příhod (registr IKTA) – je potřebný? Česká a slovenská neurologie a neurochirurgie 2013; 76(1): 23-25. [IKTA]
• Kalita Z, Brabec P, Švancara J, et al. Vyhodnocení sběru epidemiologických dat u cévních mozkových příhod z registru IKTA. Incidence cévních mozkových příhod v okrese Zlín. Česká a slovenská neurologie a neurochirurgie 2013; 76(2): 183-188. [IKTA]
• Kalita Z, Brabec P, Švancara J, et al. Rizikový profil pacientů s prodělanou ischemickou cévní mozkovou příhodou – analýza dat z registru IKTA. Česká a slovenská neurologie a neurochirurgie 2013; 76(3): 343-349. [IKTA]
• Kalita Z, Zvolský M, Švancara J, et al. Srovnání epidemiologických dat u akutních cévních mozkových příhod podle metodiky ÚZIS a IKTA ve zlínském okrese a v ČR. Česká a slovenská neurologie a neurochirurgie 2013; 76(3): 350-357. [IKTA]
• Klamová H, Machová Poláková K, Mužík J, et al. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cut-off levels. Cancer Medicine 2013; 2(2): 216-225. [CAMELIA]
• Koblížek V, Chlumský J, Zindr V, et al. Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomedical Papers 2013; 157(2): 189-201. [CHOPN]
• Kryukov F, Dementyeva EV, Kubiczková L, et al. Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. Genomics 2013; 102(4): 243–249. [RMG]
• Kryukov F, Němec P, Dementyeva E, et al. Molecular heterogeneity and centrosome-associated genes in multiple myeloma. Leukemia & Lymphoma 2013; 54(9): 1982-1988. [RMG]
• Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. International Journal of Cardiology 2013; 168(3): 2186–2194. [AHEAD]
• Parenica J, Spinar J, Vitovec J, et al. Long-term survival following acute heart failure: the Acute Heart Failure Database Main registry (AHEAD Main). European Journal of Internal Medicine 2013; 24(2): 151–160. [AHEAD]
• Pavlík, T, Janoušová, E, Mayer, J, et al. Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. American Journal of Hematology 2013; 88(9): 790-797. [CAMELIA]
• Pochop L, Hejduk K. Zpráva z „malých“ registrů – Pemetrexed, Tarceva a Yondelis. Klinická onkologie 2013; 26(1): 53-54. [Pemetrexed, Tarceva, Yondelis]
• Studnička J, Říhová B, Rencová E, et al. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice. Ophthalmologica 2013; 230(1): 34-42. [Amadeus]
• Vítek P, Strenková J, Sedláčková E, Barkmanová J, Mužík J, Louthan O. Registr neuroendokrinních nádorů (NET) v ČR po třech letech sběru dat. Klinická onkologie 2013; 26(4): 271-280. [NET]

2012

• Büchler T, Klapka R, Melichar B, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry. Annals of Oncology 2012; 23(2): 395–401. [Renis]
• Büchler T, Pavlík T, Bortlíček Z, et al. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Medical Oncology 2012; 29(5): 3321-3324. [Renis]
• Giordano L, von Karsa L, Tomatis M, et al. Mammographic screening programmes in Europe: organization, coverage and participation. Journal of Medical Screening 2012; 19(Suppl 1): 72–82. [mamo.cz]
• Grell P, Hejduk K, Vyzula R. Klinický registr BREAST. Klinická onkologie 2012; 25(3): 216-218. [Breast]
• Hofvind S, Ponti A, Patnick J, et al. False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. Journal of Medical Screening 2012; 19(Suppl 1): 57–66. [mamo.cz]
• Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. The Lancet Oncology 2012; 13(3): 265-274. [reGISTer]
• Jurečková A, Kocáková I, Vyzula R. Klinický registr GIST. Klinická onkologie 2012; 25(2): 135-138. [reGISTer]
• Málek F, Ošťádal P, Pařenica J, et al. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry. Journal of Critical Care 2012; 27(6): 737.e11–737.e24. [AHEAD]
• Němeček R, Tomášek J, Hejduk K, et al. Klinický registr CORECT. Klinická onkologie 2012; 25 (6): 480-485. [Corect]
• Pavelka K, Fojtíková M, Hejduk, K. Efficacy of the first and subsequent courses of anti-TNF therapy in patients with ankylosing spondylitis – results from the Czech National Register ATTRA. Reumatologia 2012; 50(4): 276-293. [ATTRA]
• Pavlík T, Májek O, Mužík J, et al. Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. BMC Public Health 2012; 12: 117. [kolorektum.cz]
• Poprach A, Bortlíček Z, Büchler T, et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Medical Oncology 2012; 29(5): 3314-3320. [Renis]
• Poprach A, Büchler T, Bortlíček Z, et al. Klinický registr RENIS. Klinická onkologie 2012; 25(4): 299-301. [Renis]
• Poprach A, Pavlík T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Annals of Oncology 2012; 23(12): 3137-3143. [Renis]
• Rodger S, Antonova V, Brabec P, et al. CARE-NMD: The role of patient registries in an international study of care in Duchenne muscular dystrophy. Neuromuscular Disorders 2012; 22(9): 880. [REaDY]
• Salaj P, Ovesna P, Penka M, et al. Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors. Haemophilia 2012; 18(6): e409-e411. [ČNHP]
• Salaj P, Penka M, Smejkal P, et al. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic. Thrombosis Research 2012; 129(5): e233-e237. [ČNHP]
• Studnička J, Rencová E, Rozsíval P, et al. Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry. Biomedical Papers 2012; 156(4): 359-364. [Amadeus]
• Špelda S, Skřičková J, Bortlíček Z, et al. Klinický registr TULUNG. Klinická onkologie 2012; 25(5): 383-384. [Tulung]
• Špinarová L, Špinar J, Vítovec J, et al. Gender differences in total cholesterol levels in patients with acute heart failure and its importance for short and long time prognosis. Biomedical Papers 2012; 156(1): 21–28. [AHEAD]
• Vohanka S, Mazanec R, Pavlovska L, et al. ReaDY: The Czech national registry of myotonic disorders. Neuromuscular Disorders 2012; 22(9): 881-882. [REaDY]
• Vry J, Gramsch K, Rodger S, et al. Current care practice in Duchenne Muscular Dystrophy in Europe - results of the CARE-NMD cross-sectional survey. Neuromuscular Disorders 2012; 22(9): 886-887. [REaDY]

2011

• Blatný J, Seidlová D, Penka M, et al. Severe postpartum haemorrhage treated with recombinant activated Factor VII in 80 Czech patients: analysis of the UniSeven registry. International Journal of Obstetric Anesthesia 2011; 20(4): 367-368. [UniSeven]
• Büchler T, Dušek L, Fínek J, et al. Výsledky terapie metastatického renálního karcinomu lékem everolimus – analýza údajů z klinického registru RENIS. Klinická onkologie 2011; 24(5): 389–392. [Renis]
• Faber E, Mužík J, Koza V, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry. European Journal of Haematology 2011; 87(2): 157-168. [CAMELIA]
• Felšöci M, Pařenica J, Spinar J, Vítovec J, Widimský P, Linhart A, Fedorco M, Málek F, Cíhalík C, Miklík R, Jarkovský J. Does previous hypertension affect outcome in acute heart failure? European Journal of Internal Medicine 2011; 22(6): 591–596.
• Kubáčková K, Fínek J, Vyzula R, et al. Lékový registr - trabectedin. Klinická onkologie 2011; 24(6): 470-474. [Yondelis]
• Májek O, Daneš J, Skovajsová M, et al. Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. BMC Public Health 2011; 11: 288. [mamo.cz]
• Spinar J, Ludka O, Sepsi M, et al. Atrial fibrillation as prognostic factor of myocardial infarction and/or acute heart failure. Interventional Medicine & Applied Science 2011; 3(3): 104–107. [AHEAD]
• Spinar J, Parenica J, Vitovec J, et al. Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Critical Care 2011; 15(6): R291. [AHEAD]
• Voglová J, Mužík J. Faber E, et al. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 2011; 58(3): 256-262. [CAMELIA]
• Žáčková, D, Klamová, H, Dušek, L, et al. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? American Journal of Hematology 2011; 86(3): 318-321. [CAMELIA]
• Zdziarska J, Chojnowski K, Klukowska A, et al. Registry of inherited bleeding disorders in Poland - current status and potential role of the HemoRec database. Haemophilia 2011; 17(1): e189-e195. [HemoRec]

2010

• Skřičková J, Pešek M, Zatloukal P, et al. Klinický registr TARCEVA. Klinická onkologie 2010; 23(5): 361-363. [Tulung]

2009

• Brabec P, Šufliarsky J, Linke Z, et al. A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia. Neoplasma 2009; 56(5): 459-464. [reGISTer]
• Brabec P, Vondráček P, Klimeš D, et al. Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscular Disorders 2009; 19(4): 250-254. [REaDY]
• Holzerová M, Faber E, Veselovská J, et al. Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results. Cancer Genetics and Cytogenetics 2009; 191(1): 1-9. [CAMELIA]
• Pavelka K, Forejtová S, Stolfa J, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clinical and Experimental Rheumatology 2009; 27(6): 958-963. [ATTRA]
• Puetz J, Darling G, Brabec P, et al. Thrombotic events in neonates receiving recombinant factor VIIa or fresh frozen plasma. Pediatric Blood & Cancer 2009; 53(6): 1074-1078. [SeveN Bleep]
• Salaj P, Brabec P, Penka M, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15(3): 752-759. [HemoRec]
• Smejkal P, Brabec P, Matyskova M, et al. FEIBA((R)) in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia 2009; 15(3): 743-751. [ČNHP]
• Zavoral M, Suchánek S, Závada F, et al. Colorectal cancer screening in Europe. World Journal of Gastroenterology 2009; 15(47): 5907–5915. [kolorektum.cz]

2008

• Abrahámová J, Povýšil C, Dušek L, Malbohan I, Novák J. Nádory varlat. Grada Publishing a.s., Praha 2008; 328 s. ISBN 978-80-247-2349. [Uranos]